Pharmacologic management of portal hypertension

Clinics in Liver Disease

Volumn 18, Issue 2, 2014, Pages 303-317

  Berzigotti, Annalisa ^a   Bosch, Jaime ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chronic liver disease; Drug therapy; Hepatic resistance; Portal pressure; Splanchnic blood flow

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE 5 NITRATE; MANGANESE SUPEROXIDE DISMUTASE; NADOLOL; OBETICHOLIC ACID; OCTREOTIDE; PRAZOSIN; PROPRANOLOL; RESVERATROL; SEGLITIDE; SILDENAFIL; SILYMARIN; SIMVASTATIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TERLIPRESSIN; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TIMOLOL; UNINDEXED DRUG; VAPREOTIDE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; CARBAZOLE DERIVATIVE; LYPRESSIN; PROPANOLAMINE DERIVATIVE; VASODILATOR AGENT;

ADRENERGIC RECEPTOR BLOCKING; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL PRESSURE; ASCITES; BLOOD VESSEL TONE; CACAO; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; DARK CHOCOLATE; DRUG EFFICACY; ESOPHAGUS VARICES BLEEDING; HEART OUTPUT; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; LIVER BLOOD FLOW; LIVER FUNCTION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; VASOCONSTRICTION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HYPERTENSION, PORTAL; LIVER CIRCULATION; PATHOPHYSIOLOGY; VASCULAR RESISTANCE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; CARBAZOLES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PORTAL; LIVER CIRCULATION; LYPRESSIN; PORTAL PRESSURE; PROPANOLAMINES; RENIN-ANGIOTENSIN SYSTEM; SOMATOSTATIN; SPLANCHNIC CIRCULATION; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 84897088765     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.12.003     Document Type: Review

References (82)

1. Bosch J. Vascular deterioration in cirrhosis. The big picture. JClin Gastroenterol 2007, 41:S247-S253.
2. Bosch J., Abraldes J.G., Berzigotti A., et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009, 6:573-582.
3. Groszmann R.J., Garcia-Tsao G., Bosch J., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. NEngl J Med 2005, 353:2254-2261.
4. D'Amico G., Garcia-Pagan J.C., Luca A., et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006, 131:1611-1624.
5. Kalambokis G., Economou M., Paraskevi K., et al. Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis. JGastroenterol Hepatol 2005, 20:1075-1081.
6. Merkel C., Gatta A., Bolognesi M., et al. Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 1988, 33:1103-1109.
7. Moller S., Hansen E.F., Becker U., et al. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000, 20:51-59.
8. Narahara Y., Kanazawa H., Taki Y., et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. JGastroenterol Hepatol 2009, 24:1791-1797.
9. Baik S.K., Jeong P.H., Ji S.W., et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005, 100:631-635.
10. Villanueva C., Planella M., Aracil C., et al. Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. Am J Gastroenterol 2005, 100:624-630.
11. Escorsell A., Bandi J.C., Moitinho E., et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. JHepatol 1997, 27:824-829.
12. Escorsell A., Ruiz del Arbol L., Planas R., et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 2000, 32:471-476.
13. Ioannou G.N., Doust J., Rockey D.C. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003, 17:53-64.
14. Gines P. Hepatorenal syndrome, pharmacological therapy, and liver transplantation. Liver Transpl 2011, 17:1244-1246.
15. Gerbes A.L., Huber E., Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009, 137:1179-1181.
16. Martin-Llahi M., Pepin M.N., Guevara M., et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008, 134:1352-1359.
17. Sanyal A.J., Boyer T., Garcia-Tsao G., et al. Arandomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008, 134:1360-1368.
18. Garcia-Pagan J.C., Reverter E., Abraldes J.G., et al. Acute variceal bleeding. Semin Respir Crit Care Med 2012, 33:46-54.
19. Sola E., Lens S., Guevara M., et al. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology 2010, 52:1783-1790.
20. Abraldes J.G., Bosch J. Somatostatin and analogues in portal hypertension. Hepatology 2002, 35:1305-1312.
21. Bosch J., Kravetz D., Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981, 80:518-525.
22. Villanueva C., Ortiz J., Minana J., et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001, 121:110-117.
23. Reynaert H., Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther 2003, 18:375-386.
24. Garcia-Tsao G., Bosch J. Management of varices and variceal hemorrhage in cirrhosis. NEngl J Med 2010, 362:823-832.
25. Cirera I., Feu F., Luca A., et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 1995, 22:106-111.
26. Moitinho E., Planas R., Bañares R., et al. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. JHepatol 2001, 35:712-718.
27. Albillos A., Rossi I., Iborra J., et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. JHepatol 1994, 21:88-94.
28. Ludwig D., Schadel S., Bruning A., et al. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study. Dig Dis Sci 2000, 45:1019-1027.
29. Vorobioff J.D., Gamen M., Kravetz D., et al. Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial. Gastroenterology 2002, 122:916-922.
30. Escorsell A., Bandi J.C., Andreu V., et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001, 120:161-169.
31. Lebrec D., Nouel O., Corbic M., et al. Propranolol-a medical treatment for portal hypertension?. Lancet 1980, 2:180-182.
32. Lebrec D., Nouel O., Bernuau J., et al. Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet 1981, 1:920-921.
33. Lebrec D., Poynard T., Hillon P., et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. NEngl J Med 1981, 305:1371-1374.
34. Tsochatzis E.A., Bosch J., Burroughs A.K. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012, 56:1983-1992.
35. Bosch J., Garcia-Pagan J. Prevention of variceal rebleeding. Lancet 2003, 361:952-954.
36. Escorsell A., Feu F., Bordas J.M., et al. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. JHepatol 1996, 24:423-429.
37. Garcia-Pagan J.C., Feu F., Navasa M., et al. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. JHepatol 1990, 11:189-195.
38. Grose R.D., Plevris J.N., Redhead D.N., et al. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis. JHepatol 1994, 20:542-547.
39. Navasa M., Chesta J., Bosch J., et al. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989, 96:1110-1118.
40. Bureau C., Peron J.M., Alric L., et al. "A la carte" treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002, 36:1361-1366.
41. Albillos A., Lledo J.L., Banares R., et al. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994, 20:611-617.
42. Albillos A., Lledo J.L., Rossi I., et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995, 109:1257-1265.
43. Banares R., Moitinho E., Piqueras B., et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-Alpha1- drenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999, 30:79-83.
44. Reiberger T., Ulbrich G., Ferlitsch A., et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013, 62(11):1634-1641.
45. Banares R., Moitinho E., Matilla A., et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002, 36:1367-1373.
46. Lo G.H., Chen W.C., Wang H.M., et al. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. JGastroenterol Hepatol 2012, 27:1681-1687.
47. Tripathi D., Ferguson J.W., Kochar N., et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009, 50:825-833.
48. Bosch J. Carvedilol for preventing recurrent variceal bleeding: waiting for convincing evidence. Hepatology 2013, 57:1665-1667.
49. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010, 51:2214-2218.
50. Bosch J. Carvedilol: the beta-blocker of choice for portal hypertension?. Gut 2013, 62(11):1529-1530.
51. Zafra C., Abraldes J.G., Turnes J., et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004, 126:749-755.
52. Abraldes J.G., Rodriguez-Vilarrupla A., Graupera M., et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. JHepatol 2007, 46:1040-1046.
53. Trebicka J., Hennenberg M., Laleman W., et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007, 46:242-253.
54. Abraldes J.G., Albillos A., Banares R., et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009, 136:1651-1658.
55. La Mura V., Pasarin M., Garcia-Pagan J.C., et al. Effects of simvastatin administration on liver microvascular dysfunction induced by LPS. JHepatol 2011, 54:S48.
56. Tandon P., Abraldes J.G., Berzigotti A., et al. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. JHepatol 2010, 53:273-282.
57. Garcia-Pagan J.C., Gracia-Sancho J., Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. JHepatol 2012, 57:458-461.
58. Berzigotti A., Garcia-Tsao G., Bosch J., et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011, 54:555-561.
59. Berzigotti A., Abraldes J.G. Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. Gastroenterol Hepatol 2013, 36(8):527-533.
60. Delgado M.G., Gracia-Sancho J., Marrone G., et al. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2013, 305(7):G496-G502.
61. Cohen-Naftaly M., Friedman S.L. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011, 4:391-417.
62. Gracia-Sancho J., Lavina B., Rodriguez-Vilarrupla A., et al. Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability. Hepatology 2008, 47:1248-1256.
63. Hernandez-Guerra M., Garcia-Pagan J.C., Turnes J., et al. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology 2006, 43:485-491.
64. Matei V., Rodriguez-Vilarrupla A., Deulofeu R., et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006, 44:44-52.
65. Matei V., Rodriguez-Vilarrupla A., Deulofeu R., et al. Three-day tetrahydrobiopterin therapy increases invivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats. JHepatol 2008, 49:192-197.
66. Lavina B., Gracia-Sancho J., Rodriguez-Vilarrupla A., et al. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut 2009, 58:118-125.
67. Garcia-Caldero H., Rodriguez-Vilarrupla A., Gracia-Sancho J., et al. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. JHepatol 2011, 54:660-665.
68. Guillaume M., Rodriguez-Vilarrupla A., Gracia-Sancho J., et al. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. JHepatol 2013, 58:240-246.
69. Verbeke L., Farre R., Trebicka J., et al. Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2013 Nov 20, [Epub ahead of print]. 10.1002/hep.26939.
70. Rodriguez-Vilarrupla A., Lavina B., Garcia-Caldero H., et al. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. JHepatol 2012, 56:1033-1039.
71. Di Pascoli M., Divi M., Rodriguez-Vilarrupla A., et al. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. JHepatol 2013, 58:904-910.
72. de Gottardi A., Berzigotti A., Seijo S., et al. Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. Am J Clin Nutr 2012, 96:584-590.
73. Graupera M., Garcia-Pagan J.C., Pares M., et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. JHepatol 2003, 39:515-521.
74. Rosado E., Rodriguez-Vilarrupla A., Gracia-Sancho J., et al. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats. Hepatology 2013, 58(4):1424-1435.
75. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. NEngl J Med 2010, 362:1071-1081.
76. Vlachogiannakos J., Saveriadis A.S., Viazis N., et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009, 29:992-999.
77. Vlachogiannakos J., Viazis N., Vasianopoulou P., et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. JGastroenterol Hepatol 2013, 28:450-455.
78. Fernandez M., Semela D., Bruix J., et al. Angiogenesis in liver disease. JHepatol 2009, 50:604-620.
79. Bosch J., Abraldes J.G., Fernandez M., et al. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. JHepatol 2010, 53:558-567.
80. Mejias M., Garcia-Pras E., Tiani C., et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009, 49:1245-1256.
81. Coriat R., Gouya H., Mir O., et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One 2011, 6:e16978.
82. Pinter M., Sieghart W., Reiberger T., et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma-a pilot study. Aliment Pharmacol Ther 2012, 35:83-91.